Methotrexate in combination with sulfasalazine is more effective in rheumatoid arthritis patients who failed sulfasalazine than in patients naïve to both drugs

Rheumatology

Volumn 48, Issue 7, 2009, Pages 828-833

  Schipper, Lydia G ^a   Fransen, Jaap ^a   Barrera, Pilar ^a   Van Riel, Piet L C M ^a  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Combination drug therapy; Methotrexate; Rheumatoid arthritis; Sulfasalazine; Therapeutic use

Indexed keywords

METHOTREXATE; SALAZOSULFAPYRIDINE;

ADD ON THERAPY; ARTICLE; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; DISEASE ACTIVITY; DRUG EFFICACY; DRUG EXPOSURE; DRUG TREATMENT FAILURE; HUMAN; MONOTHERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RHEUMATOID ARTHRITIS; SCORING SYSTEM; SYSTEMATIC REVIEW; TREATMENT RESPONSE;

ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; MALE; METHOTREXATE; MIDDLE AGED; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SULFASALAZINE; TREATMENT OUTCOME;

EID: 67650073255     PISSN: 14620324     EISSN: 14620332     Source Type: Journal    
DOI: 10.1093/rheumatology/kep090     Document Type: Article

References (33)

1. Boers M. Add-on or step-up trials for new drug development in rheumatoid arthritis: A new standard? Arthritis Rheum 2003;48:1481-3.
2. Arnett FC, Edworthy SM, Bloch DA et al. The American Rheumatism Association 1987 revised criteria for the classification of rheumatoid arthritis. Arthritis Rheum 1988;31:315-24.
3. Van der Heijde DM, van't Hof M, van Riel PL, van de Putte LB. Development of a disease activity score based on judgment in clinical practice by rheumatologists. J Rheumatol 1993;20:579-81.
4. Felson DT, Anderson JJ, Boers M et al. American College of Rheumatology. Preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995;38:727-35.
5. Capell HA, Madhok R, Porter DR, Munro RA, McInnes IB, Hunter JA et al Combination therapy with sulfasalazine and methotrexate is more effective than either drug alone in patients with rheumatoid arthritis with a suboptimal response to sulfasalazine: Results from the double-blind placebo-controlled MASCOT study. Ann Rheum Dis 2007;66:235-41.
6. Dougados M, Combe B, Cantagrel A et al. Combination therapy in early rheumatoid arthritis: A randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components. Ann Rheum Dis 1999;58:220-5.
7. Haagsma CJ, van Riel PL, de Rooij DJ et al. Combination of methotrexate and sulphasalazine vs methotrexate alone: A randomized open clinical trial in rheumatoid arthritis patients resistant to sulphasalazine therapy. Br J Rheumatol 1994; 33:1049-55.
8. Haagsma CJ, van Riel PL, de Jong AJ, van de Putte LB. Combination of sulphasalazine and methotrexate versus the single components in early rheumatoid arthritis: A randomized, controlled, double-blind, 52 week clinical trial. Br J Rheumatol 1997;36:1082-8.
9. Haagsma CJ, van Riel PL, van de Putte LB. Combining sulphasalazine and methotrexate in rheumatoid arthritis: Early clinical impressions. Br J Rheumatol 1995;34(Suppl. 2):104-8.
10. Maillefert JF, Combe B, Goupille P, Cantagrel A, Dougados M. Long term structural effects of combination therapy in patients with early rheumatoid arthritis: Five year follow up of a prospective double blind controlled study. Ann Rheum Dis 2003;62:764-6.
11. Nisar M, Carlisle L, Amos RS. Methotrexate and sulphasalazine as combination therapy in rheumatoid arthritis. Br J Rheumatol 1994;33:651-4.
12. O'Dell JR, Haire CE, Erikson N et al. Treatment of rheumatoid arthritis with methotrexate alone, sulfasalazine and hydroxychloroquine, or a combination of all three medications. N Engl J Med 1996;334:1287-91.
13. O'Dell JR, Leff R, Paulsen G et al. Treatment of rheumatoid arthritis with methotrexate and hydroxychloroquine, methotrexate and sulfasalazine, or a combination of the three medications: Results of a two-year, randomized, double-blind, placebo-controlled trial. Arthritis Rheum 2002;46:1164-70.
14. Riksen NP, Barrera P, van den Broek PH, van Riel PL, Smits P, Rongen GA. Methotrexate modulates the kinetics of adenosine in humans in vivo. Ann Rheum Dis 2006;65:465-70.
15. Gadangi P, Longaker M, Naime D et al. The anti-inflammatory mechanism of sulfasalazine is related to adenosine release at inflamed sites. J Immunol 1996;156:1937-41.
16. van Ede AE, Laan RF, Blom HJ, De Abreu RA, van de Putte LB. Methotrexate in rheumatoid arthritis: An update with focus on mechanisms involved in toxicity. Semin Arthritis Rheum 1998;27:277-92.
17. Jansen G, van der HJ, Oerlemans R et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: Implications for combination therapies with methotrexate in rheumatoid arthritis. Arthritis Rheum 2004;50:2130-9.
18. Bourke RS, Chheda G, Bremer A, Watanabe O, Tower DB. Inhibition of renal tubular transport of methotrexate by probenecid. Cancer Res 1975;35: 110-6.
19. Haagsma CJ, Russel FG, Vree TB, van Riel PL, van de Putte LB. Combination of methotrexate and sulphasalazine in patients with rheumatoid arthritis: Pharmacokinetic analysis and relationship to clinical response. Br J Clin Pharmacol 1996;42:195-200.
20. van der HJ, de Jong MC, Dijkmans BA, Lems WF, Oerlemans R, Kathmann I et al. Acquired resistance of human T cells to sulfasalazine: stability of the resistant phenotype and sensitivity to non-related DMARDs. Ann Rheum Dis 2004; 63:131-7.
21. Wessels JA, de Vries-Bouwstra JK, Heijmans BT et al. Efficacy and toxicity of methotrexate in early rheumatoid arthritis are associated with single-nucleotide polymorphisms in genes coding for folate pathway enzymes. Arthritis Rheum 2006;54:1087-95.
22. Dervieux T, Furst D, Lein DO et al. Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis. Arthritis Rheum 2004;50:2766-74.
23. James HM, Gillis D, Hissaria P et al. Common polymorphisms in the folate pathway predict efficacy of combination regimens containing methotrexate and sulfasalazine in early rheumatoid arthritis. J Rheumatol 2008;35:562-71.
24. Wessels JA, van der Kooij SM, le Cessie S et al. A clinical pharmacogenetic model to predict the efficacy of methotrexate monotherapy in recent-onset rheumatoid arthritis. Arthritis Rheum 2007;56:1765-75.
25. Selhub J, Dhar GJ, Rosenberg IH. Inhibition of folate enzymes by sulfasalazine. J Clin Invest 1978;61:221-4.
26. Smolen JS, Aletaha D, Machold KP. Therapeutic strategies in early rheumatoid arthritis. Best Pract Res Clin Rheumatol 2005;19:163-77.
27. Wolfe F, Rehman Q, Lane NE, Kremer J. Starting a disease modifying antirheumatic drug or a biologic agent in rheumatoid arthritis: standards of practice for RA treatment. J Rheumatol 2001;28:1704-11.
28. Quinn MA, Conaghan PG, Emery P. The therapeutic approach of early intervention for rheumatoid arthritis: What is the evidence? Rheumatology 2001;40:1211-20.
29. Weinblatt ME. The role of current strategies in the future treatment of rheumatoid arthritis. Rheumatology 1999;38(Suppl. 2):19-23.
30. Boers M, Verhoeven AC, Markusse HM et al. Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis. Lancet 1997;350:309-18.
31. Goekoop-Ruiterman YP, Vries-Bouwstra JK, Allaart CF et al. Clinical and radiographic outcomes of four different treatment strategies in patients with early rheumatoid arthritis (the BeSt study): a randomized, controlled trial. Arthritis Rheum 2005;52:3381-90.
32. van der Kooij SM, de Vries-Bouwstra JK, Goekoop-Ruiterman YP et al Limited efficacy of conventional DMARDs after initial methotrexate failure in patients with recent onset rheumatoid arthritis treated according to the disease activity score. Ann Rheum Dis 2007;66:1356-62.
33. Morabito L, Montesinos MC, Schreibman DM et al. Methotrexate and sulfasalazine promote adenosine release by a mechanism that requires ecto-5′-nucleotidase-mediated conversion of adenine nucleotides. J Clin Invest 1998;101:295-300.